Literature DB >> 8707401

Overexpression and mutations of p53 in metastatic malignant melanomas.

A Hartmann1, H Blaszyk, J S Cunningham, R M McGovern, J S Schroeder, S D Helander, M R Pittelkow, S S Sommer, J S Kovach.   

Abstract

Alterations of the p53 tumor suppressor gene are the most frequent genetic abnormalities in human malignancies, but the role of p53 in the etiology of malignant melanomas is unclear. Fifty unselected malignant melanomas were analyzed for p53 overexpression by immunohistochemistry using 3 monoclonal antibodies (MAbs). Fifteen tumors (29.4%) showed positive staining with at least 2 different antibodies. In the first 20 consecutive tumors exons 5-9 and adjacent splice sites of the p53 gene were analyzed by genomic sequencing. There were 4 mutations in 20 metastatic melanomas. Three of 4 mutations were C:G-->T:A transitions. A search of our database of p53 mutations revealed that out of 8 p53 mutations reported by others, 4 are C:G-->T:A transitions at dipyrimidine sites, and one is a tandem CC-->TT mutation. This mutational pattern is comparable with the pattern of p53 mutations in squamous cell and basal cell carcinomas of the skin and is related to exposure to ultraviolet B (UV-B) wavelength radiation. Taken together with a predominance of UV-induced mutations in the CDKN2/ p16 gene demonstrated in melanoma cell lines, our data support a role of sunlight exposure in the etiology of malignant melanoma. The low frequency of p53 mutants in melanomas compared with other types of skin cancers suggests that although mutations in this gene are likely to be involved in the development of some malignant melanomas, they do not play as large a role as in squamous and basal cell carcinomas of the skin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8707401     DOI: 10.1002/(SICI)1097-0215(19960729)67:3<313::AID-IJC1>3.0.CO;2-U

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  Similar nucleotide excision repair capacity in melanocytes and melanoma cells.

Authors:  Shobhan Gaddameedhi; Michael G Kemp; Joyce T Reardon; Janiel M Shields; Stephanie L Smith-Roe; William K Kaufmann; Aziz Sancar
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

2.  Mutation and homozygous deletion analyses of genes that control the G1/S transition of the cell cycle in skin melanoma: p53, p21, p16 and p15.

Authors:  José Luis Soto Martínez; Carmen M Cabrera Morales; Sabio Serrano Ortega; Miguel Angel López-Nevot
Journal:  Clin Transl Oncol       Date:  2005-05       Impact factor: 3.405

3.  Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium.

Authors:  K Margolin; J Longmate; T W Synold; D R Gandara; J Weber; R Gonzalez; M J Johansen; R Newman; T Baratta; J H Doroshow
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

4.  p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation.

Authors:  Tamara Terzian; Enrique C Torchia; Daisy Dai; Steven E Robinson; Kazutoshi Murao; Regan A Stiegmann; Victoria Gonzalez; Glen M Boyle; Marianne B Powell; Pamela M Pollock; Guillermina Lozano; William A Robinson; Dennis R Roop; Neil F Box
Journal:  Pigment Cell Melanoma Res       Date:  2010-12       Impact factor: 4.693

5.  EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression.

Authors:  Tao Fan; Shunlin Jiang; Nancy Chung; Ali Alikhan; Christina Ni; Chyi-Chia Richard Lee; Thomas J Hornyak
Journal:  Mol Cancer Res       Date:  2011-03-07       Impact factor: 5.852

6.  Prognostic significance of Sox4 expression in human cutaneous melanoma and its role in cell migration and invasion.

Authors:  Seyed Mehdi Jafarnejad; Aijaz Ahmad Wani; Magdalena Martinka; Gang Li
Journal:  Am J Pathol       Date:  2010-10-15       Impact factor: 4.307

7.  The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes.

Authors:  Hong Yu; Ronan McDaid; John Lee; Patricia Possik; Ling Li; Suresh M Kumar; David E Elder; Patricia Van Belle; Phyllis Gimotty; Matt Guerra; Rachel Hammond; Katharine L Nathanson; Maria Dalla Palma; Meenhard Herlyn; Xiaowei Xu
Journal:  Am J Pathol       Date:  2009-04-23       Impact factor: 4.307

8.  Mechanism of UV-related carcinogenesis and its contribution to nevi/melanoma.

Authors:  Brozyna Anna; Zbytek Blazej; Granese Jacqueline; Carlson J Andrew; Ross Jeffrey; Slominski Andrzej
Journal:  Expert Rev Dermatol       Date:  2007

9.  Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B.

Authors:  José Luis Soto; Carmen M Cabrera; Salvio Serrano; Miguel Angel López-Nevot
Journal:  BMC Cancer       Date:  2005-04-08       Impact factor: 4.430

10.  p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis.

Authors:  S F Zerp; A van Elsas; L T Peltenburg; P I Schrier
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.